U.S. equity indices closed little changed on Wednesday, August 19, 2026, with the S&P 500 slipping just 0.02% to 7,675.70, the Dow Jones Industrial Average down 0.21% to 53,463.88, and the Nasdaq Composite off 0.08% to 26,130.20. Beneath that quiet headline number, the session carried three distinct catalysts: a Treasury Department move to calm the long end of the bond market, minutes from the Federal Reserve's July meeting, and a record-setting surge in Moderna shares. Chip stocks lagged as investors rotated into healthcare and consumer cyclicals, leaving the broad averages roughly flat by the close.
Treasury Buyback Eases Bond Market Strain
Long-dated Treasury yields had climbed to some of their highest levels in nearly two decades earlier in the week, pressuring equities as the cost of long-term government borrowing rose alongside concerns over deficits and AI-driven capital spending. On Wednesday the Treasury Department said it would more than double the maximum size of its debt buyback operations, from 2 billion dollars to at least 4 billion dollars, with the accelerated purchases targeting the 10-to-20-year and 20-to-30-year segments of the curve that had seen thin demand since late June. The announcement pulled yields lower and helped the S&P 500 snap a three-day losing streak, even as the index finished only marginally changed by the close.
Fed Minutes Reveal a Divided Committee
The Federal Reserve released minutes from its July 28-29 meeting at 2 p.m. Eastern, confirming a 9-3 vote to hold the policy rate at 3.5% to 3.75%, with three officials favoring a quarter-point hike. Participants described the labor market as broadly in balance but flagged elevated uncertainty around inflation, growth, and the outlook for prices, with some willing to raise rates further if progress stalled. New Fed Chair Kevin Warsh reportedly floated the idea of moving to six policy meetings a year instead of eight, though no decision was taken and the existing 2026 calendar stands. The minutes reinforced a cautious, data-dependent tone heading into Jackson Hole.
Moderna's Record Surge Reshapes the Healthcare Trade
The standout move of the day came from outside the macro narrative. Moderna shares jumped as much as 177% after the company and partner Merck reported that their individualized mRNA cancer therapy, combined with Merck's Keytruda, met its primary recurrence-free survival endpoint in a Phase 3 melanoma trial. Volume ran at roughly 28 times the average as short sellers, who had wagered on a continued slump, absorbed billions of dollars in losses. The move lifted sentiment across healthcare and biotech names broadly and contributed to the sector-led rotation that offset weakness in technology shares for much of the session.
Chip Weakness Sets the Stage for Next Week
Technology and semiconductor names underperformed even as broader indices held steady, with Nvidia among the decliners ahead of its widely anticipated quarterly report due after the close the following week. The divergence between a resilient headline index and a softer AI-linked complex suggests investors are trimming exposure into two major catalysts still ahead: Nvidia's earnings and the Jackson Hole symposium, where new Fed Chair Kevin Warsh is due to deliver his first keynote address. With the FOMC minutes underscoring a split committee and long-end yields still historically elevated, positioning into that stretch is likely to stay cautious and sensitive to fresh headlines.
Daily market analysis by BCM Markets.